{"title":"A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. ad hoc Study Group.","authors":"G Finazzi, T Barbui","doi":"10.1007/BF02900709","DOIUrl":null,"url":null,"abstract":"<p><p>The clinical records of 103 Italian patients with inherited thrombophilia and thrombosis were reviewed to estimate the incidence of thrombotic recurrences and major bleeding complications according to the different duration of oral anticoagulant prophylaxis (OAP). The incidence of the first thrombotic recurrence was 2.9, 7.4 and 10.8 x 100 patients/year, respectively, in subjects receiving lifelong OAP, stopping OAP after a mean of 9 months (range 1-30 months) or not receiving OAP. The probability to remain free from thrombotic recurrences in patients undergoing lifelong OAP, as estimated by the Kaplan-Meier method, was significantly higher in comparison with untreated patients (p less than 0.001), but did not reach the statistical significance in comparison with patients who stopped prophylaxis. The incidence of further thrombotic recurrences was 1.2, 21.1 and 22.3 x 100 patients/year, respectively, in the three groups defined above. The difference between patients who prolonged indefinitely OAP vs those who stopped or did not receive OAP was statistically significant (p = 0.003). Two intracranial bleedings, one of which fatal, were observed in patients undergoing lifelong OAP, whereas no major bleeding complications occurred in the other two groups. Our study supports the recommendations to continue indefinitely OAP in patients with inherited thrombophilia and recurrent thrombosis, but suggests caution in starting lifelong prophylaxis soon after the first thrombotic event in all patients.</p>","PeriodicalId":76092,"journal":{"name":"La Ricerca in clinica e in laboratorio","volume":"20 4","pages":"245-52"},"PeriodicalIF":0.0000,"publicationDate":"1990-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02900709","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Ricerca in clinica e in laboratorio","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02900709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
Abstract
The clinical records of 103 Italian patients with inherited thrombophilia and thrombosis were reviewed to estimate the incidence of thrombotic recurrences and major bleeding complications according to the different duration of oral anticoagulant prophylaxis (OAP). The incidence of the first thrombotic recurrence was 2.9, 7.4 and 10.8 x 100 patients/year, respectively, in subjects receiving lifelong OAP, stopping OAP after a mean of 9 months (range 1-30 months) or not receiving OAP. The probability to remain free from thrombotic recurrences in patients undergoing lifelong OAP, as estimated by the Kaplan-Meier method, was significantly higher in comparison with untreated patients (p less than 0.001), but did not reach the statistical significance in comparison with patients who stopped prophylaxis. The incidence of further thrombotic recurrences was 1.2, 21.1 and 22.3 x 100 patients/year, respectively, in the three groups defined above. The difference between patients who prolonged indefinitely OAP vs those who stopped or did not receive OAP was statistically significant (p = 0.003). Two intracranial bleedings, one of which fatal, were observed in patients undergoing lifelong OAP, whereas no major bleeding complications occurred in the other two groups. Our study supports the recommendations to continue indefinitely OAP in patients with inherited thrombophilia and recurrent thrombosis, but suggests caution in starting lifelong prophylaxis soon after the first thrombotic event in all patients.
本文回顾了意大利103例遗传性血栓形成患者的临床记录,根据口服抗凝预防(OAP)的不同持续时间估计血栓复发和主要出血并发症的发生率。在接受终身OAP治疗、平均9个月(1-30个月)后停止OAP治疗或未接受OAP治疗的患者中,首次血栓复发率分别为2.9、7.4和10.8 x 100例/年。Kaplan-Meier方法估计,终身OAP患者无血栓复发的概率显著高于未治疗的患者(p < 0.001),但与停止预防的患者相比,未达到统计学意义。在上述三组中,进一步血栓复发的发生率分别为1.2、21.1和22.3 x 100例/年。无限期延长OAP的患者与停止或未接受OAP的患者之间的差异具有统计学意义(p = 0.003)。在终身OAP患者中观察到两次颅内出血,其中一次是致命的,而在其他两组中没有发生重大出血并发症。我们的研究支持对遗传性血栓和复发性血栓患者无限期继续OAP治疗的建议,但建议在所有患者首次血栓事件发生后不久开始终身预防。